Genmab A (GMAB) Dividends Paid - Common (2023 - 2026)
Genmab A's (GMAB) quarterly Dividends Paid - Common came in at $1.5 billion in Q1 2026, down 6.05% YoY from $1.6 billion in Q1 2025, and down 13.63% on a QoQ basis from $1.8 billion in Q3 2025.
Genmab A (GMAB) Dividends Paid - Common (2023 - 2026) Analysis & Trends
Genmab A (GMAB) has 4 years of Dividends Paid - Common data on file, last reported at $1.5 billion in Q1 2026.
- Quarterly Dividends Paid - Common fell 6.05% year-over-year to $1.5 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $6.2 billion (up 35.51% YoY) and the FY2024 annual result came in at $1.4 billion, down 37.39% from the prior year.
- Dividends Paid - Common eased to $1.5 billion in Q1 2026, from $1.8 billion in the prior quarter.
- In the past five years, Dividends Paid - Common ranged from a high of $2.2 billion in Q4 2023 to a low of $622.0 million in Q2 2024.
- A 4-year average of $1.5 billion and a median of $1.5 billion in 2026 frame the typical range for Dividends Paid - Common.
- Annual changes were most pronounced in 2024 — Dividends Paid - Common tumbled 37.39% — and 2025, when it surged 108.36%.
- Tracing GMAB's Dividends Paid - Common over 4 years: stood at $2.2 billion in 2023, then tumbled by 37.39% to $1.4 billion in 2024, then increased by 27.61% to $1.8 billion in 2025, then dropped by 13.63% to $1.5 billion in 2026.
- The last three Dividends Paid - Common figures came in at $1.5 billion (Q1 2026), $1.8 billion (Q3 2025), and $1.3 billion (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Dividends Paid - Common (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 96.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | - |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 34.60 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | - |
| 10 | Genmab A | 2.05 Bn | 548.77 Mn | 1.07 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.52 Bn |
| Mar 31, 2026 | 1.52 Bn |
| Sep 30, 2025 | 1.76 Bn |
| Sep 30, 2025 | 1.76 Bn |
| Jun 30, 2025 | 1.30 Bn |
| Jun 30, 2025 | 1.30 Bn |
| Mar 31, 2025 | 1.62 Bn |
| Mar 31, 2025 | 1.62 Bn |
| Dec 31, 2024 | 1.38 Bn |
| Dec 31, 2024 | 1.38 Bn |
| Sep 30, 2024 | 952.00 Mn |
| Sep 30, 2024 | 952.00 Mn |
| Jun 30, 2024 | 622.00 Mn |
| Jun 30, 2024 | 622.00 Mn |
| Mar 31, 2024 | 2.13 Bn |
| Mar 31, 2024 | 2.13 Bn |
| Dec 31, 2023 | 2.20 Bn |
| Dec 31, 2023 | 2.20 Bn |